A Phase I Single-Dose Open-Label Two-Way Fixed-Sequence Study Evaluating The Effect Of Rolapitant On The Radiolabeled NK-1 ligand Tracer [11C]-GR205171 In The Brains Of Healthy Volunteers Using PET Imaging: PET Study

Trial Profile

A Phase I Single-Dose Open-Label Two-Way Fixed-Sequence Study Evaluating The Effect Of Rolapitant On The Radiolabeled NK-1 ligand Tracer [11C]-GR205171 In The Brains Of Healthy Volunteers Using PET Imaging: PET Study

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Rolapitant (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors TESARO
  • Most Recent Events

    • 10 Feb 2017 New trial record
    • 31 Jan 2017 Results published in the Clinical Pharmacology and Therapeutics Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top